8-KMaterial AgreementsOther EventsExhibits & Filings

AMGEN INC 8-K Report, Material Agreement (Nov 2, 2017)

Filed November 2, 2017For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on November 2, 2017, to report a material definitive agreement related to a debt issuance. The Company issued and sold $1 billion of 3.200% Senior Notes due 2027. The net proceeds from this offering are approximately $990.4 million, after accounting for underwriting discounts and estimated offering expenses. These notes are a component of Amgen's broader financing strategy and are registered under a previously filed Form S-3. The issuance aims to strengthen the company's financial position and potentially fund ongoing operations and strategic initiatives. Key terms of the Notes include a maturity date of November 2, 2027, and semi-annual interest payments of 3.200% per annum, paid on May 2 and November 2, starting May 2, 2018. A significant provision is the change in control clause, which allows noteholders to require Amgen to repurchase their notes at 101% of the principal amount plus accrued interest in the event of a specified change in control triggering event. Investors should note that these senior notes rank equally with existing and future senior unsecured debt but are subordinated to the obligations of Amgen's subsidiaries and any secured obligations.

Key Highlights

  • 1Amgen Inc. issued $1 billion in 3.200% Senior Notes due 2027.
  • 2Net proceeds from the offering amounted to approximately $990.4 million.
  • 3The Notes mature on November 2, 2027, with semi-annual interest payments.
  • 4A change in control provision allows noteholders to demand repurchase at 101% of principal plus interest.
  • 5The Notes rank pari passu with existing and future senior unsecured indebtedness.
  • 6The issuance was registered under a previously filed Form S-3.
  • 7The filing also includes the computation of Amgen's ratio of earnings to fixed charges.

Frequently Asked Questions

This 8-K filing primarily announces Amgen Inc.'s entry into a material definitive agreement, specifically the issuance and sale of $1 billion of its 3.200% Senior Notes due 2027. It provides details about the terms of these notes and the net proceeds received.

The filing states that the net proceeds to the Company were approximately $990.4 million after deducting underwriters’ discounts and estimated offering expenses. While the specific use of proceeds is not detailed in this 8-K, such debt issuances typically aim to fund general corporate purposes, capital expenditures, potential acquisitions, or refinance existing debt.

The 3.200% Senior Notes due 2027 will bear interest at a rate of 3.200% per annum, payable semi-annually on May 2 and November 2. The notes will mature on November 2, 2027.

In the event of a change in control triggering event, noteholders can require Amgen to repurchase their notes at 101% of the principal amount plus accrued interest. The notes rank equally with Amgen's other senior unsecured indebtedness and senior to its subordinated indebtedness. However, they are effectively subordinated to the obligations of Amgen's subsidiaries and subordinated to Amgen's secured obligations to the extent of the collateral.